Document Detail


Matrix metalloproteinases: drug targets for myocardial infarction.
MedLine Citation:
PMID:  23316962     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patients, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.
Authors:
Andriy Yabluchanskiy; Yaojun Li; Robert J Chilton; Merry L Lindsey
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current drug targets     Volume:  14     ISSN:  1873-5592     ISO Abbreviation:  Curr Drug Targets     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-27     Completed Date:  2013-08-14     Revised Date:  2014-03-06    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  276-86     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Movement
Collagen / metabolism
Fibronectins / metabolism
Humans
Laminin / metabolism
Macrophages / physiology
Matrix Metalloproteinase Inhibitors / therapeutic use*
Myocardial Infarction / drug therapy*
Myofibroblasts / physiology
Neutrophil Infiltration
Proteoglycans / metabolism
Ventricular Remodeling
Grant Support
ID/Acronym/Agency:
HHSN268201000036C/HL/NHLBI NIH HHS; N01-HV-00244/HV/NHLBI NIH HHS; R01 HL075360/HL/NHLBI NIH HHS; R01 HL075360/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Fibronectins; 0/Laminin; 0/Matrix Metalloproteinase Inhibitors; 0/Proteoglycans; 9007-34-5/Collagen
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mountain laurel toxicosis in a dog.
Next Document:  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins...